




RealRate

PHARMACEUTICAL 2020

Phathom Pharmaceuticals Inc
Rank 137 of 363

Phathom.
PHARMACEUTICALS



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Phathom Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Phathom Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 117% points. The greatest weakness of Phathom Pharmaceuticals Inc is the variable Other Net Income, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is 281%, being 43% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	255,601
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,748
Liabilities, Non-Current	2,698
Other Assets	1,114
Other Compr. Net Income	0
Other Expenses	78,897
Other Liabilities	22,777
Other Net Income	-148,916
Other Revenues	0
Property and Equipment	463
Research and Development	20,374
Selling, General and Administrative Expense	6,944

Output Variable	Value in 1000 USD
Assets	257,178
Liabilities	29,223
Expenses	106,215
Revenues	0
Stockholders Equity	227,955
Net Income	-255,131
Comprehensive Net Income	-255,131
BaseVar	270,766
ECR before Limited Liability	169%
Economic Capital Ratio	281%